A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Latest Information Update: 13 Feb 2025
At a glance
- Drugs SGN-TGT (Primary) ; Brentuximab vedotin; Sasanlimab
- Indications Advanced breast cancer; Bladder cancer; Carcinoma; Diffuse large B cell lymphoma; Gastric cancer; Head and neck cancer; Hodgkin's disease; Lymphoma; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peripheral T-cell lymphoma; Skin cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Seagen
Most Recent Events
- 17 Jan 2024 Status changed from active, no longer recruiting to discontinued.
- 08 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 11 May 2023 Planned number of patients changed from 429 to 417.